+44 (0) 20 7079 4399
Call HCA from 8am-8pm Mon-Fri and 9am-5pm Sat
HCA Healthcare UK
Professor Mark Emberton
MD, FRCS Urol
Prostate cancers, benign prostate hyperplasia, Prostatitis, High Intensity Focused Ultrasound (HIFU), Electroporation
114a Harley Street
Mark Emberton holds the post of Professor in Interventional Oncology at University College London and is Associate Professor at Middlesex University, London. At UCLH he is Pathway Director for Urological Cancer for UCL Partners. He is also Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. His clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In prostate cancer much of his activity is at present focused on evaluating minimally invasive therapies for localised prostate cancer. This work encompasses the fields of precise characterisation of disease as well as targeting therapies. A current interest includes the non invasive evaluation of men at risk of having prostate cancer. Professor Emberton is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomised control trial in surgery. He is involved in guideline production and appraisal and is interested in the formulation of evidence based management policies. He is an active researcher, lectures widely and has published over 100 peer reviewed publications as well as numerous books and chapters. He is a founding Partner of London Urology Associates, and is a Trustee of Prostate Action.
Call the contact centre
+44 (0) 20 7079 4399
8am-8pm Mon-Fri, 9am-5pm Sat
Let us call you backCan we call you back at a more convenient time
Email contact centreSend us an email and we will get back to you.
© copyright 2008 - 2017 HCA Healthcare UK.
Registered Name: HCA International Limited; The part of the UK in which it is registered: England and Wales;
Registered Number: 03020522; Registered Office Address: 242 Marylebone Road London NW1 6JL.
£500m has been invested by HCA International in the latest medical technologies and facilities over the last 10 years.
Your hospital will be one of our world-class private hospitals: HCA’s world-class hospitals are accredited by The CHKS Accreditation Unit, a leading provider of healthcare intelligence and quality improvement services. The accreditation is a measure of the overall quality of a hospital and hospitals with CHKS accreditation have been shown to provide a better quality of service.
Your safety will be protected because we have more critical care beds than any other private hospital group: HCA hospitals achieved 100% compliance with all Care Quality Commission inspected outcomes of care in 2011.
Your treatment will be undertaken using the most advanced diagnostic and treatment facilities: Oliver Wyman, Corporate Accounts: Driving quality and value, January 2012.